VitriVax, Inc.
PrivateLast Round
Series B
Oct 22, 2025
Total Funding Raised
$70.6M
Company Overview
VitriVax, Inc. operates in Healthcare & Life Sciences and is based in Boulder, Colorado. Its latest recorded funding round was a Series B round in October 2025.
VitriVax, Inc. is a biotechnology company that develops a vaccine formulation platform (ALTA®) designed to enable thermostable, single-shot administration of vaccines and therapeutics.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Pharma Supply Chain
Business Model
B2B
Customer Profile
Government Contracts, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
VitriVax, Inc. Comparables
Compare VitriVax, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| EnsiliTech | 78% | |
| Universal Stabilization Technologies | 77% | |
| Elarex Inc. | 77% |
For institutional investors. Book with your work email.
VitriVax, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Oct 22, 2025 | ||||
| Grant | Oct 14, 2025 | ||||
| Grant | Apr 28, 2025 | ||||
| Grant | Dec 4, 2024 | ||||
| Grant | Dec 6, 2023 | ||||
Grant | Jan 12, 2023 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
VitriVax, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| RA Capital Management | Series B |
| CEPI | Grant |
| Gates Family Foundation | Grant |
| Gates Foundation | Grant |
| Bill & Melinda Gates Foundation | Grant |
| The Bill & Melinda Gates Foundation Trust | Grant |
| Adjuvant Capital | Series B, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 18, 2026
Monthly visitors increased 291% MoM.
- Oct 22, 2025
$17.25M round closed.
For institutional investors. Book with your work email.
VitriVax, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about VitriVax, Inc.'s valuation, stock price, and market status.
Is VitriVax, Inc. a public or private company?
VitriVax, Inc. is a private company.
What is the current stock price of VitriVax, Inc.?
VitriVax, Inc. is a private company, so its shares have no public market price. Caplight tracks VitriVax, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is VitriVax, Inc. worth (valuation)?
Valuation information for VitriVax, Inc. is not publicly available.
Can I buy VitriVax, Inc. stock?
VitriVax, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was VitriVax, Inc.'s last funding round?
VitriVax, Inc.'s most recent funding round was Series B on October 22, 2025.
Who are the main investors in VitriVax, Inc.?
Key investors in VitriVax, Inc. include RA Capital Management, Bill & Melinda Gates Foundation, Adjuvant Capital.
Will VitriVax, Inc. IPO soon?
No public IPO plans have been announced for VitriVax, Inc..
How can I track VitriVax, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in VitriVax, Inc.'s shares on secondary markets.